NSCLC Hub Header
opdivo-dtc-util-nav

Indications

Prescribing Information

Next Page Icon

Medication Guide

Next Page Icon
Potential OPDIVO® (nivolumab) user spending time in his backyard with his grandchildren.
Potential OPDIVO® (nivolumab) user spending time in his backyard with his grandchildren.

Clinical trial results for
advanced non-small cell
lung cancer (NSCLC)

For certain adults with advanced non-small cell lung cancer (NSCLC) that tests positive for PD-L1

Actor portrayals.
OPDIVO + YERVOY is not approved for people
younger than 18 years of age.

An FDA-approved combination of two immunotherapies that helped people live longer compared to platinum-based chemotherapy

About the clinical trial

In a clinical trial of 793 people with previously untreated NSCLC whose tumors tested positive for programmed death-ligand 1
(PD-L1), 396 people were given OPDIVO + YERVOY and 397 people were given platinum-based chemotherapy.

People given OPDIVO + YERVOY lived longer compared to platinum-based chemotherapy

At 17 months, half the people given OPDIVO® + YERVOY® were alive.
OPDIVO + YERVOY

Half the people were alive

At 15 months, half the people given only platinum-based chemotherapy were alive.
Platinum-based chemotherapy 

Half the people were alive

In the primary analysis with a minimum follow-up of 29 months, people given OPDIVO + YERVOY had a 21% lower risk of dying than those given platinum-based chemotherapy.

OPDIVO + YERVOY will not work for everyone. Individual results may vary.

“Going forward is the most important thing. Step by step."


Stacy’s story

Stacy knows her family has her back. Her husband and sisters showed unwavering support when she was diagnosed, especially when she was diagnosed with advanced lung cancer and treated with OPDIVO + YERVOY.

Stacy knows her family has her back. That’s why her husband and sisters decided to always keep her smiling, especially when she was diagnosed with advanced lung cancer and treated with OPDIVO + YERVOY.

“Utilize everything at your disposal...then come up with the best treatment between you and your doctor."


John’s story

John is a Navy veteran and a father of four who loves to travel. Learn about his experience with advanced lung cancer and OPDIVO + YERVOY.

John, a veteran and father, shares his experience with advanced NSCLC and OPDIVO® (nivolumab) + YERVOY® (ipilimumab).

Should I ask my doctor about OPDIVO + YERVOY?

Talk to your doctor about a potential first treatment option for advanced lung cancer.

Man searching for how to fight non-small cell lung cancer with OPDIVO® (nivolumab) + YERVOY® (ipilimumab).
Hands exploring how OPDIVO® (nivolumab) works and learning how this treatment may help fight cancer.

How treatment works

See how this treatment may help your body fight cancer

OPDIVO® (nivolumab) side effects.

Side effects

View side effects of treatment and learn how to manage them

Nurse monitoring a gentleman's infusion of OPDIVO® (nivolumab) immunotherapy treatment.

Getting an infusion

See your recommended treatment plan and what to expect from an infusion

For certain adults with advanced non-small cell lung cancer (NSCLC) that tests positive for PD-L1

OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) as a first treatment for adults with a type of advanced stage lung cancer (called non-small cell lung cancer) when your lung cancer has spread to other parts of your body (metastatic) and your tumors are positive for PD-L1, but do not have an abnormal EGFR or ALK gene.

It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.

It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.

OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.



1506-US-2400468 09/24